AYTU
NASDAQ · Pharmaceuticals
Aytu Biopharma Inc
$1.83
+0.02 (+1.11%)
Financial Highlights (FY 2026)
Revenue
49.40M
Net Income
-12,229,893
Gross Margin
63.9%
Profit Margin
-24.8%
Rev Growth
-18.8%
D/E Ratio
0.48
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 63.9% | 63.9% | 29.4% | 29.4% |
| Operating Margin | -14.4% | -13.0% | 29.7% | 36.1% |
| Profit Margin | -24.8% | -23.5% | 29.2% | 27.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 49.40M | 60.82M | 4.25M | 5.07M |
| Gross Profit | 31.59M | 38.89M | 1.25M | 1.49M |
| Operating Income | -7,133,746 | -7,903,941 | 1.26M | 1.83M |
| Net Income | -12,229,893 | -13,550,293 | 1.24M | 1.37M |
| Gross Margin | 63.9% | 63.9% | 29.4% | 29.4% |
| Operating Margin | -14.4% | -13.0% | 29.7% | 36.1% |
| Profit Margin | -24.8% | -23.5% | 29.2% | 27.0% |
| Rev Growth | -18.8% | -18.8% | +20.1% | +11.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.15M | 3.15M | 1.90M | 1.72M |
| Total Equity | 6.52M | 6.52M | 20.49M | 17.88M |
| D/E Ratio | 0.48 | 0.48 | 0.09 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -4,997,035 | -5,844,125 | 1.93M | 2.61M |
| Free Cash Flow | — | — | 869.5K | 889.0K |